Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2006

View Archived Issues

Long-term hepatitis C virus suppression seen with valopicitabine and peg-interferon

Bavituximab safe in phase I hepatitis C study

Phase II study shows eltrombopag efficacy in HCV-associated thrombocytopenia

Studies detail long-term hepatitis B viral suppression with telbivudine

Interferon alfacon-1/ribavirin shows promise in HCV peg-interferon nonresponders

Idenix to enhance hepatitis C pipeline through Metabasis collaboration

Daytrana shown to give individualized ADHD symptom management

Phase III study of naproxcinod in osteoarthritis meets primary endpoints

Intercell and MSD to develop prophylactic vaccine against Group A Streptococcus

Action Pharma's pipeline development supported by new venture capital

RTA-744 awarded orphan drug status for malignant gliomas

Shionogi discontinues development of S-5751

Strattera improves ADHD symptoms in subjects with reading disorder

R-7128 begins phase I study for HCV

Argos awarded NIH contract to further develop HIV immunotherapy candidates

New phase I study to investigate WT1 peptide therapeutic vaccine INNO-305

Chugai reviews highlights of third quarter

Preclinical studies of FTI tipifarnib encourage clinical investigation in HGPS

Fluphenazine decanoate to be evaluated for the management of psoriasis in phase II clinical trial

Nicotinamide protects against axonal degeneration in MS model / News in Context

Emerging natural products for the treatment of neurological disorders: Part I

New treatments for cancer covered in recent patent literature

Recent Pfizer patent describes new dopamine D2 receptor ligands for schizophrenia

Novel alpha1A/1D-adrenoceptor antagonists reported by Janssen

Novel agents for dental caries claimed by Queen Mary, University of London

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...